NCT04672733

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

Recruiting · Not specified · CSL Behring · registry updated 2025-01-07

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).

Inclusion

Adult patient (aged ≥18 years)
Patients suffering from CIDP according to EAN/PNS 2021 criteria
Planned switch from IVIg to Hizentra®
Patient treated with at least 3 courses of IV immunoglobulin and deemed by the investigator to be dependent on immunoglobulins
Patient deemed to be stable, with no change in their treatment for the disease during the 3 months prior to inclusion
Patients who have a smartphone, a tablet or a computer

Exclusion

Concomitant participation in an interventional clinical study

Open NCT04672733 on ClinicalTrials.gov All conditions